Lilly alliance to progress promising new approach to treating Alzheimer's disease

Lilly’s pipeline of potential medicines and diagnostic agents has been bolstered by our alliance with AstraZeneca, which shares our passion to bring new medicines to patients suffering from this debilitating illness. This alliance moves us one step closer to achieving our goal of making Alzheimer’s dementia preventable by 2025.

David Ricks Lilly Senior Vice President and President, Lilly Bio-Medicines